Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: AD04 in early Alzheimer's disease
2024-518523-30-00Phase 2Suspended
- Sponsor
- ADvantage Therapeutics
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AD04 with Placebo (2 arms). Primary endpoint: Composite efficacy endpoint. Started Dec 2024; status: suspended.
02
Drugs
AD04
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-518523-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518523-30-00.